短期与长期腔内灌注吡柔比星预防浅表性膀胱癌术后复发的比较  

Short-versus long-term intravesical instillation of pirarubicin for preventing postoperative recurrence of superficial bladder cancer

作　　者：华立新[1] 吴宏飞[1] 徐承良[1] 钱立新[1] 张杰秀[1] 程双管[1] 

机构地区：[1]南京医科大学第一附属医院泌尿外科,南京210029

出　　处：《临床泌尿外科杂志》2004年第5期287-288,共2页Journal of Clinical Urology

摘　　要：目的 :比较短期和长期腔内灌注吡柔比星对预防浅表性膀胱癌术后复发的效果。方法 :将 5 6例浅表性膀胱癌患者术后随机分为两组 ,A组 (2 8例 )行吡柔比星 30mg膀胱灌注 ,每周 1次 ,共 8次 ;B组 (2 8例 )前 8次灌注同A组 ,以后改为每月 1次至术后 1年。随访 2年 ,观察肿瘤复发率和副反应发生情况。结果 :1年肿瘤复发率 :A组 2例 (7.2 % ) ,B组 1例 (3.7% ) ,差异无统计学意义 (χ2 =0 .5 76 ,P >0 .0 5 )。 2年肿瘤复发率 :A组 3例 (10 .7% ) ,B组 4例 (14 .3% ) ,差异亦无统计学意义 (χ2 =0 .384 ,P >0 .0 5 )。副反应发生情况 :A组 3例(10 .7% ) ,B组 8例 (2 8.6 % ) ,A组不良反应发生率低于B组 (χ2 =12 .36 ,P <0 .0 1)。结论 :吡柔比星短期腔内灌注预防浅表性膀胱癌术后复发疗效肯定 ,副作用小。Objective:To compare short-term with long-term intravesical instillation of pirarubicin(THP) for preventing postoperative recurrence of superficial bladder cancer.Method: Fifty-six postoperative patients with superficial bladder cancer were randomized into groups A:30 mg THP, once a week for 8 weeks; B:30 mg THP, once a week for 8 weeks, then once a month for 1 year. All the patients were followed up for 2 years. The tumor recurrence rate and the side effects associated with therapy were observed.Result:The tumor recurrence rate were 7.2%, 3.7%(χ 2= 0.576,P> 0.05) in group A and group B at 1 year, and 10.7%, 14.3%(χ 2= 0.384,P> 0.05) at 2 year after operation, respectively. Side effects of group A( 10.7%) were lower than those of group B( 28.6%)(χ 2= 12.36, P< 0.01).Conclusion:Short-term intravesical instillation of THP for preventing postoperative recurrence of superficial bladder cancer is effective and feasible, and the side effects are mild.

关 键 词：膀胱肿瘤 吡柔比星 膀胱灌注 

分 类 号：R737.14[医药卫生—肿瘤]